<DOC>
	<DOCNO>NCT01324076</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , doxorubicin , work different way stop growth cancer cell , either kill cell stop dividing . Chemoembolization kill tumor cell carry drug directly tumor block blood flow tumor . Sorafenib tosylate may stop growth tumor cell block enzymes need cell growth block blood flow tumor . It yet know whether transarterial chemoembolization use doxorubicin-eluting bead effective give without sorafenib tosylate treat patient liver cancer remove surgery . PURPOSE : This randomized phase III trial study give transarterial chemoembolization use doxorubicin-eluting bead sorafenib tosylate see well work compare give transarterial chemoembolization use doxorubicin-eluting bead placebo treat patient liver cancer remove surgery .</brief_summary>
	<brief_title>Transarterial Chemoembolization Using Doxorubicin Beads With Without Sorafenib Tosylate Treating Patients With Liver Cancer That Can Be Removed By Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine whether addition sorafenib tosylate transarterial chemoembolization ( TACE ) doxorubicin-eluting bead , compare TACE alone , prolongs progression-free survival patient unresectable hepatocellular carcinoma . Secondary - To determine add sorafenib tosylate TACE prolongs overall survival patient . - To determine sorafenib tosylate regimen prolongs time progression patient . - To determine acceptable toxicity relate sorafenib tosylate regimen patient . - To determine effect sorafenib tosylate regimen disease response , term complete response , partial response , stable disease , patient . - To determine effect sorafenib tosylate regimen quality life patient . - To determine treatment sorafenib tosylate regimen reduce frequency repeat TACE measure number TACE procedures perform 12 month . - To establish blood sample bank link study biomarker research ( proteomic genomic analysis ) . OUTLINE : This multicenter study . Patients stratify accord randomize center serum alpha-fetoprotein level ( &lt; 400 ng/mL v ≥ 400 ng/mL ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral sorafenib tosylate twice daily absence disease progression unacceptable toxicity . Beginning within 2-5 week start sorafenib tosylate , patient undergo transarterial chemoembolization ( TACE ) doxorubicin-eluting bead . Patients may undergo additional session TACE doxorubicin-eluting bead , absence complete devascularization tumor ( ) ( assess follow-up contrast enhanced scan ) . - Arm II : Patients receive oral placebo twice daily absence disease progression unacceptable toxicity . Beginning within 2-5 week start placebo , patient undergo TACE doxorubicin-eluting bead arm I . Patients disease progression may cross sorafenib tosylate arm discretion treat clinician follow survival . Blood sample may collect baseline periodically pharmacogenetic pharmacokinetic study . Patients complete EORTC QoL questionnaire ( QLQ-C30 ) version 3 EORTC QLQ-HCC18 ( site-specific module HCC ) baseline periodically study . After completion study therapy , patient follow periodically 1 year . Peer Reviewed Funded Endorsed Cancer Research UK .</detailed_description>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm hepatocellular carcinoma ( HCC ) OR meet American Association Study Liver Diseases ( AASLD ) criteria diagnosis HCC Unresectable disease Not amenable liver transplantation At least one unidimensionally measurable lesion accord RECIST criterion CT scan MRI ChildPugh A ( score ≤ 6 ) ChildPugh cirrhosis C B ( score ≥ 7 ) No ascites refractory diuretic therapy No document occlusion hepatic artery main portal vein No extrahepatic metastasis hepatic encephalopathy PATIENT CHARACTERISTICS : ECOG performance status 01 Life expectancy &gt; 3 month Hemoglobin ≥ 9 g/L Absolute neutrophil count ≥ 1.5 x 10^9/L Platelet count ≥ 60,000/μL Bilirubin ≤ 50 μmol/L Alkaline phosphatase &lt; 4 time upper limit normal ( ULN ) AST ALT &lt; 5 time ULN Creatinine ≤ 1.5 time ULN Amylase lipase &lt; 2 time ULN INR ≤ 1.5 LVEF ≥ 45 % Able swallow oral medication Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception study 3 month completion study treatment No history bleed within past 4 week No contraindication hepatic embolization procedure , include portosystemic shunt , hepatofugal blood flow , know severe atheromatosis No hypersensitivity intravenous contrast agent No active clinically serious infection &gt; grade 2 ( NCICTC version 4 ) No known history HIV infection No history second malignancy except nonmelanotic skin cancer cervical carcinoma situ malignancy treat curative intent &gt; 3 year without relapse No evidence severe uncontrolled disease include follow : Systemic disease Cardiac arrhythmia ( require antiarrhythmic therapy pacemaker ) Hypertension NYHA class III IV congestive cardiac failure Myocardial infarction within past 6 month Laboratory finding , view Investigator , make undesirable patient participate trial No psychiatric disorder likely impact inform consent PRIOR CONCURRENT THERAPY : At least 4 week since prior concurrent investigational therapy No prior embolization , systemic therapy , radiotherapy HCC No major surgery within past 4 week No ablative therapy ( radiofrequency ablation percutaneous ethanol injection ) HCC Patients untreated target lesion ( ) ablation occur &gt; 6 week prior study entry allow No concurrent rifampicin St. John wort No concurrent bone marrow transplant stem cell rescue No concurrent bevacizumab drug target VEGF VEGF receptors No concurrent anticancer chemotherapy , immunotherapy , hormone therapy , molecular therapy except bisphosphonates</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>adult primary hepatocellular carcinoma</keyword>
	<keyword>localize unresectable adult primary liver cancer</keyword>
	<keyword>advanced adult primary liver cancer</keyword>
</DOC>